Merck & Company Inc (MRK)vsZevra Therapeutics Inc. (ZVRA)
MRK
Merck & Company Inc
$149.57
+1.79%
HEALTHCARE · Cap: $355.10B
ZVRA
Zevra Therapeutics Inc.
$11.67
+0.52%
HEALTHCARE · Cap: $689.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 48822% more annual revenue ($66.57B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.64. ZVRA earns a higher WallStSmart Score of 63/100 (C+).
MRK
Hold36
out of 100
Grade: F
ZVRA
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$149.57
$66.53 premium
Margin of Safety
+64.8%
Fair Value
$24.07
Current Price
$11.67
$12.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : ZVRA
The strongest argument for ZVRA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.95 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (63/100 vs 36/100), backed by strong 42.8% margins and 53.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?